key: cord-0745390-9vfwqv91 authors: Nourian, Anahid; Khalili, Hossein title: Sofosbuvir as a potential option for the treatment of COVID-19 date: 2020-05-11 journal: Acta Biomed DOI: 10.23750/abm.v91i2.9609 sha: 387c6c1b90063152aba91a430e93fe8c5b8870a3 doc_id: 745390 cord_uid: 9vfwqv91 Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies. (www.actabiomedica.it) Sofosbuvir is a direct-acting antiviral agent with NS5B RNA-dependent RNA polymerase (RdRp) inhibitory activity that was approved for the treatment of HCV infection in 2013. In 2014 the combination of sofosbuvir and ledipasvir (a NS5A protein inhibitor) received US FDA approval for the treatment of viral hepatitis caused by genotype 1of HCV (1). Sofosbuvir may be a potential option in the treatment of COV-ID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. HCV NS5B RdRp requires nucleotide triphosphates as substrates to synthesize RNA, a process without proofreading function (2) . Drugs such as sofosbuvir act like these substrates, which terminate the RNA synthesis process by incorporating into the RNA chain (3) . Coronaviruses are single-stranded RNA viruses (4). The RNA is translated into numerous proteins including structural proteins (S, N, M and E proteins), non-structural proteins (NSP) such as nsp12 (RdRp) and proteases (PLpro and 3CLpro) (4) . There are only two docking studies regarding the potential activity of sofosbuvir against coronavirus RdRp. One has been reported in 2016, 4 years after Middle East respiratory syndrome coronavirus outbreak, and the other one has been targeted in 2020 (5) (6) . Sofosbuvir can inhibit RdRp by fitting into the active site of the structural model of coronavirus and forms the bond with the virus polymerase. There is also a virtual screening for ledipasvir, an inhibitor of the NS5A protein, to assess its ability to attach to 3CL pro of the 2019 coronavirus (7). It is suggested that ledipasvir (in combination with sofosbuvir) may be a candidate to inhibit the proteins of coronavirus. There is no specific data about the 50% of maximum inhibitory concentration (IC 50 ) of sofosbuvir against coronavirus but there are for hepatitis C, hepatitis E, hepatitis A, zika, dengue and West Nile virus. Different values of IC 50 have been measured by different methods for some virus subtypes and cell lines. Activity of sofosbuvir against the recombinant viruses also has been examined (8) . Several replicons of HCV inhibited with IC 50 of 0.016 -0.048µM (9) . In another in-vitro study, IC 50 of sofosbuvir against HCV was 1.2µM (10) . The inhibitory activity of sofosbuvir against HEV has been reported with an IC 50 of 1.2µM and 10 µM, based on the different replicons (11) . There is also an-other report of dose-dependent inhibition of sofosbuvir on HEV with an IC 50 of 1.97µM (12) . However, it was claimed that sofosbuvir did not effective against HEV even at high concentrations (13) . Sofosbuvir may also be active against hepatitis A virus (14) . This drug inhibited HAV polymerase with IC 50 of 6.3µM in hepatic but not in kidney cell line. Activity of sofosbuvir against West Nile virus (WNV) was also examined on different cell lines by Dragoni et al. (15) . The IC 50 values of sofosbuvir were1.2µM and 63.4µM for WNV in hepatic and lung cells respectively. As a concern, activity of sofosbuvir was inferior in the lung cells. There are some experiences regarding efficacy of sofosbuvir against zika virus (ZIKV). The IC 50 values of 1-5µM were reported for 3 strains of ZIKV in hepatic cell lines and 12-44µM in placental cell lines (16) . In hepatic cell line, sofosbuvir IC 50 values were 2.0µM and 3.8µM against ZIKV and Dengue virus (DENV), respectively (17) . In another report sofosbuvir inhibited ZIKV replication with IC 50 value of 0.38µM (18) . Mumtaz et al evaluated the effectiveness of sofosbuvir against ZIKV in different cell lines (Huh7, Vero and A549) (19) . They detected IC 50 of 4µM for sofosbuvir but only in hepatic cells. The concentration of the drug was much lower in kidney and lung cell lines. Other examinations on different cell lines are needed to evaluate the activity of sofosbuvir in tissues other than hepatic cells. In conclusion, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies. Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opinion on Drug Metabolism & Toxicology Nucleoside/nucleotide analogue polymerase inhibitors in development From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral research Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrobial agents and chemotherapy Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin Antiviral candidates for treating hepatitis E virus infection Distinct antiviral potency of sofosbuvir against hepatitis C and E viruses Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro The FDA-approved drug sofosbuvir inhibits Zika virus infection Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication Cell-line dependent antiviral activity of sofosbuvir against Zika virus E-mail: khalilih@sina.tums.ac.ir